BioCentury | Jul 18, 2019
Distillery Therapeutics

Inhibition of BACH1 or the genes it controls for metastatic lung cancer

...and shorter survival. In human lung cancer cells, an shRNA against BACH1, the MCT1 inhibitor AZD3965...
...HK2 or GADPH, decreased cell migration. In mice with the disease, the shRNA against BACH1, AZD3965...
...and GADPH decreased the number of metastases. AstraZeneca plc and Cancer Research Technology Ltd. have AZD3965...
BioCentury | Jun 10, 2013
Clinical News

AZD3965: Phase I started

...open-label, dose-escalation, U.K. Phase I trial to evaluate 5, 10, 20 and 30 mg oral AZD3965...
...arm. Cancer Research Technology Ltd. , London, U.K. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: AZD3965...
BioCentury | Aug 15, 2011
Product Development

Powering down cancer

...overexpressed in many tumor types, but not in normal tissue. AstraZeneca and CRT are developing AZD-3965...
...that is planned to begin this year. AstraZeneca has an option to reacquire rights to AZD-3965...
...and alpha-ketoglutarate dehydrogenase Hematological malignancies; solid tumors Ph I/II AstraZeneca plc (LSE:AZN; NYSE:AZN)/Cancer Research UK AZD-3965...
Items per page:
1 - 3 of 3